NASDAQ:NEUP Neuphoria Therapeutics 2/17/2026 Earnings Report $5.20 -0.14 (-2.53%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neuphoria Therapeutics EPS ResultsActual EPS-$0.77Consensus EPS -$0.56Beat/MissMissed by -$0.21One Year Ago EPSN/ANeuphoria Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Announcement DetailsQuarterDate2/17/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNeuphoria Therapeutics' next earnings date is estimated for Tuesday, May 19, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Neuphoria Therapeutics Earnings HeadlinesNeuphoria Therapeutics (NASDAQ:NEUP) Stock Price Up 1.3% - Should You Buy?May 5 at 2:33 AM | americanbankingnews.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comLouis Navellier: “I'm dropping everything on May 13.” Here's why.47-year Wall Street veteran Louis Navellier says a rare market pattern is forming for only the fifth time in his career - each previous instance was triggered by a Federal Reserve shift and preceded gains of 1,100% to 2,900% in select small-cap stocks. On May 13 at 1 p.m. ET, Navellier is hosting the 10X Fed Shock Summit to walk through what he sees unfolding before the new Fed Chair takes over on May 15. Sign up and receive his 53-stock 'Exclusion List' free, plus his single highest-conviction pick named live.May 8 at 1:00 AM | Stansberry Research (Ad)Neuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comSee More Neuphoria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email. Email Address About Neuphoria TherapeuticsNeuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.View Neuphoria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem Remains Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
